Posaconazole bioavailability of the solid oral tablet is reduced during severe intestinal mucositis-Reference-Cited by-同舟云学术

Posaconazole bioavailability of the solid oral tablet is reduced during severe intestinal mucositis

Published:2022-07 Issue:7 Volume:28 Page:1003-1009
ISSN:1198-743X
Container-title:Clinical Microbiology and Infection
language:en
Short-container-title:Clinical Microbiology and Infection

Author:

Jansen Anouk M.E.,Muilwijk Eline W.,van der Velden Walter J.F.M.,Maertens Johan A.,Aerts Robina,Colbers Angela,Burger David,Verweij Paul E.,ter Heine Rob,Blijlevens Nicole M.A.,Brüggemann Roger J.M.

Funder

Merck Sharp & Dohme Ltd

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference32 articles.

1. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia;Maertens;J Antimicrob Chemother,2018

2. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America;Patterson;Clin Infect Dis,2016

3. Biomarkers and non-invasive tests for gastrointestinal mucositis;Kuiken;Support Care Cancer,2017

4. Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis;Dolton;Antimicrob Agents Chemother,2014

5. A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis;Bryant;Int J Antimicrob Agents,2011

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Posaconazole gastro-resistant tablets for preventing invasive fungal disease after haematopoietic stem cell transplantation: a propensity-matched cohort study;Clinical Microbiology and Infection;2024-07

2. Dosing of IV posaconazole to treat critically ill patients with invasive pulmonary aspergillosis: a population pharmacokinetics modelling and simulation study;Journal of Antimicrobial Chemotherapy;2024-06-03

3. Population Pharmacokinetic Modeling of Posaconazole in Japanese Patients Receiving Fungal Prophylaxis;Therapeutic Drug Monitoring;2024-04-04

4. Factors Influencing Serum Posaconazole Concentrations in Patients With Hematologic Malignancies Receiving Delayed-Release Tablets;Therapeutic Drug Monitoring;2024-04-04

5. Personalized Antifungal Therapy Through Model-Informed Precision Dosing of Posaconazole;Clinical Pharmacokinetics;2024-03-26